Alerta

DYNAMIC ADJUSTMENT OF A CORRECTION FACTOR OF A USER BASED ON GLUCOSE VALUES

Resumen de: WO2025038566A1

The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.

IMPLANTABLE GLUCOSE SENSOR

Resumen de: MX2023009042A

Disclosed herein is an implantable glucose sensor (1, 1', 1'', 1''', 1'''') for determining impedance in tissue of a living being, the implantable glucose sensor comprises: - a housing (2, 2'), - two injecting electrodes (4, 4') for injecting current into the tissue, - two sensing electrodes (5) for measuring impedance in the tissue, whereby the two sensing electrodes (5) are arranged separately from the two injecting electrodes (4, 4'), - a coil (7) arranged within the housing (2, 2') for powering the implantable glucose sensor via a power source (10), - a circuit board (8) arranged within the housing (2, 2'), the circuit board (8) being electrically connected to the two sensing electrodes (5) and the two injecting electrodes (4, 4') and the coil (7), - a communication unit (9) for transferring and receiving data packages, the communication unit (9) being connected to the circuit board (8), and wherein the housing (2) comprises a first part (3a) and a second part (3b, 3b'). The two sensing electrodes (5) and the two injecting electrodes (4, 4') are arranged on an outer surface of the first part (3a). The outer surface of first part (3a) is of a convex shape and in that the two sensing electrodes (5) and the two injecting electrodes (4, 4') are embedded in the convex shape so that they are flush with the outer surface of the convex shape.

ANALYTE SENSORS AND SENSING METHODS FEATURING DUAL DETECTION OF GLUCOSE AND KETONES

Resumen de: EP4509046A2

Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.

PCSEL FOR GLUCOSE MONITORING

Resumen de: EP4510398A2

This disclosure describes a glucose monitor with one or more photonic crystal surface-emitting lasers (PCSELs). The PCSEL comprises a plurality of photonics crystal sections. Each photonics crystal section is operable to emit light of a different wavelength. The horizontal emission by each photonics crystal section may be constrained by edge lattice sections.

BLOOD COLLECTION AND BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: EP4509049A1

A lancing and blood glucose level measuring device includes a casing; a laser oscillation unit that is accommodated within the casing and configured to generate a laser beam for blood sampling; a blood glucose level measuring unit that is accommodated within the casing and configured to measure a blood glucose level; a contact unit that is formed on a part of one side of the casing and configured to irradiate the laser beam toward an irradiation target area; a blood glucose strip insertion unit which is formed on another part of one side of the casing and into which a blood glucose strip including a blood glucose sensor that transmits and receives signals to and from the blood glucose level measuring unit to measure a blood glucose level is to be inserted; and a controller configured to control the laser oscillation unit.

BLOOD GLUCOSE PREDICTION METHOD AND DEVICE COMBINING BIG DATA MODEL AND PERSONALIZED MODEL

Resumen de: EP4509045A1

A blood glucose prediction method and device combining a big data model and a personalized model. The method comprises: training a big data blood glucose prediction model; receiving a first collection data set of a specified object; when a first data type is a label type, according to the first collection data set, updating a personalized data base; if the updating is successful, counting the total number of personalized data records to generate a first total number; if the first total number is greater than or equal to a first threshold value, screening personalized data calibrated records; if the first total number is equal to a second threshold value, training a personalized blood glucose prediction model; when the first data type is a prediction type, counting the total number of personalized data records to generate a second total number; if the second total number is smaller than the second threshold value, on the basis of the big data blood glucose prediction model, making a prediction; and if the second total number is equal to the second threshold value, on the basis of the big data blood glucose prediction model and the personalized blood glucose prediction model, making a personalized blood glucose prediction. The method can avoid the inconvenience of invasive blood glucose tests.

Analyte sensors and sensing methods for detecting inhibitors of diaphorase

Resumen de: AU2025200491A1

Analyte sensors featuring an enzyme system comprising diaphorase and a NAD-dependent dehydrogenase may be utilized to detect inhibitors of diaphorase, provided that the transfer of electrons to a working electrode is rate-limiting with respect to the diaphorase. Such analyte sensors may comprise a sensor tail comprising at least a first working electrode, a first active area disposed upon a surface of the first working electrode, and an analyte-permeable membrane overcoating at least the first active area. The enzyme system comprises NAD, reduced NAD, or any combination thereof; a NAD-dependent dehydrogenase, such as NAD-dependent glucose dehydrogenase; and diaphorase. Inhibitors of diaphorase that may be detected include, for example, warfarin, dicoumarol, and similar compounds. A second active area may be present to facilitate detection of an analyte differing from the inhibitor of diaphorase.

SYSTEM COORDINATOR AND MODULAR ARCHITECTURE FOR OPEN-LOOP AND CLOSED-LOOP CONTROL OF DIABETES

Resumen de: US2025054597A1

A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025049396A1

The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.

CONTINUOUS ANALYTE MONITORING SYSTEM WITH MICRONEEDLE ARRAY

Resumen de: US2025049397A1

Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.

ELECTRONIC DEVICE AND ESTIMATION SYSTEM

Resumen de: US2025049353A1

An estimation system comprises at least one processor; and at least one non-transitory medium connected to the at least one processor. The at least one processor is programmed to perform acquiring input information including a pulse wave of a first subject; and estimating the blood glucose level or a glucose metabolism of the first subject based on an estimation expression. The estimation expression is based on a blood glucose level and a pulse wave corresponding to the blood glucose level, and based on a result of regression analysis using an Augmentation Index given by a ratio of a magnitude of a forward wave of the pulse wave and a reflected wave emerging after the forward wave.

ANALYTE MONITORING: STABILIZER FOR SUBCUTANEOUS GLUCOSE SENSOR WITH INCORPORATED ANTIGLYCOLYTIC AGENT

Resumen de: US2025049350A1

An analyte sensor including an antiglycolytic agent or a precursor thereof and a chelating agent that stabilizes the antiglycolytic agent positioned proximate to the working electrode of the sensor. Also provided are systems and methods of using the electrochemical analyte sensors in analyte monitoring.

SYSTEMS AND METHODS FOR PROVIDING THERAPY MANAGEMENT RECOMMENDATIONS FOR DIABETIC PATIENTS AND PATIENTS WITH LIVER DISEASE

Resumen de: US2025049355A1

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor and convert the sensor current generated by the continuous analyte sensor into digital signals, one or more processors configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.

MICRO MODELS AND LAYERED PREDICTION MODELS FOR ESTIMATING SENSOR GLUCOSE VALUES AND REDUCING SENSOR GLUCOSE SIGNAL BLANKING

Resumen de: US2025049352A1

Methods, systems, and devices for improving continuous glucose monitoring (“CGM”) are described herein. More particularly, the methods, systems, and devices describe applying micro machine learning models to generate predicted sensor glucose values. The system may use the predicted sensor glucose values to display a sensor glucose value to a user. The layered models may generate more reliable sensor glucose predictions across many scenarios, leading to a reduction of sensor glucose signal blanking. The methods, systems, and devices described herein further comprise applying a plurality of micro model to estimate sensor glucose values under outlier conditions. The system may prioritize the models that are trained for certain outlier conditions when the system detects those outlier condition based on the sensor data.

BLOOD GLUCOSE ESTIMATION USING NEAR INFRARED LIGHT EMITTING DIODES

Resumen de: US2025049324A1

Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.

LIQUID MEDICINE INJECTION APPARATUS

Resumen de: US2025050012A1

A Liquid medicine injection apparatus includes: a needle portion having one or more needle bodies configured to be injected into a user's body, a reservoir portion configured to accommodate a medical liquid and receive power from a driving portion to deliver the medical liquid to the needle portion, a base portion on which the reservoir portion, the needle portion, and the driving portion are installed, a cover portion covering the base portion, and a sensor portion configured to measure blood sugar. In the cover portion, an insertion groove which has one side open and has a preset depth is formed, and the sensor portion is insertable into the insertion groove and is spatially separable from the base portion.

INFUSION PUMP SYSTEM WITH DISPOSABLE CARTRIDGE HAVING PRESSURE VENTING AND PRESSURE FEEDBACK

Resumen de: US2025050017A1

Embodiments are directed to portable infusion devices, systems, and methods of using the same for dispensing materials. In some cases, the devices, systems and methods may be used for infusing a material such as medicament, e.g., insulin, into a body in need thereof.

SYSTEMS, DEVICES, AND METHODS FOR ANALYTE MONITORING

Resumen de: US2025050019A1

A glucose monitoring system comprising a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level of a subject, and a reader device. The reader device comprises a wireless communication circuitry configured to receive the data indicative of the analyte level and a glycated hemoglobin level for the subject, a non-transitory memory, and at least one processor communicatively coupled to the non-transitory memory and the analyte sensor and configured: calculate a plurality of personalized glucose metrics for the subject using at least one physiological parameter and at least one of the received data indicative of the analyte level or the received glycated hemoglobin level, and a display, on a display of the reader device, a report comprising a plurality of interfaces including at least two or more of the received data indicative of the analyte level, the received glycated hemoglobin level, or the calculated plurality of personalized glucose metrics, wherein the plurality of interfaces comprising the report are based on a user type.

ADJUSTABLE GLUCOSE COST COMPONENT IN A COST FUNCTION FOR DETERMINING BASAL DELIVERY DOSES IN A MEDICAMENT DELIVERY SYSTEM

Resumen de: US2025050021A1

Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.

SYSTEM AND METHOD FOR ADJUSTING THERAPY BASED ON RISK ASSOCIATED WITH A GLUCOSE STATE

Resumen de: CN106456063A

The present disclosure relates to a system and method for determining a basal rate adjustment based on risk associated with a glucose state of a person with diabetes. The method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state. The method may include identifying a reference glucose state and a reference risk metric associated with the reference glucose state, and calculating an adjustment to a basal rate of a therapy delivery device based on the current risk metric associated with the detected glucose state and the reference risk metric associated with the reference glucose level.

A skin patch wearable biosensor for simultaneous monitoring of physiological parameters in interstitial fluid

Resumen de: GB2632399A

The device 100 comprises hollow microneedles 106 and a substrate 102 that uses capillary action to extract interstitial fluid (ISF) from the skin of the user. The ISF is analysed by an electrochemical sensor 104 that measures a physiological parameter. The ISF may collect in a reservoir 112. The microneedles may have pyramidal tips and cuboidal bodies (6, 7, fig 1E). The microneedle channels may have a hydrophilic coating. The monitored parameters may be alcohol levels, drug levels, glucose levels, or oxygenation levels. There may be a processor that determines parameter levels from the sensor signal, and wireless communications that will transmit that level to a separate receiver. The device may be modular with the sampling and sensor part (200, fig 3D) being separate from the processing and communications part (300, fig 3D). The device may be attached using a sticky patch, or a strap (400, fig 3D).

ELECTRONIC RING FOR MONITORING BLOOD GLUCOSE LEVELS

Resumen de: WO2023195020A1

The proposed invention relates to a method of determining a blood glucose level of a user. The method comprises obtaining, by a Photoplethysmography (PPG) sensor (302), raw data related to pulsations of a user. The raw data is filtered by a Data Signal Processing (DSP) filter to obtain derived variables related to variations in blood viscosity. The raw data is further processed by a probabilistic model to obtain secondary variables related to operating conditions of a circulatory and respiratory system of the user. Readings of the PPG sensor (302) are obtained by a microcontroller (306). The readings of the PPG sensor (302) indicates intensity values of reflections of light transmitted by the PPG sensor onto a blood vessel of the user. The readings of the PPG sensor (302) are processed based on the derived variables and the secondary variables to determine a blood glucose level of the user.

ANALYTE SENSORS FEATURING DUAL DETECTION OF GLUCOSE AND KETONES

Resumen de: JP2024052892A

To provide an analyte sensor and a sensing method featuring dual detection of glucose and ketones.SOLUTION: Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together by using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, and a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system including at least two enzymes that are capable of acting in concert to facilitate detection of ketones.SELECTED DRAWING: Figure 2A

BODY ATTACHABLE UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Resumen de: US2025040838A1

The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.

METHOD FOR DETERMINING THE CONCENTRATION OF A SUBSTANCE AND DETECTOR ARRANGMENT

Nº publicación: US2025040841A1 06/02/2025

Solicitante:

AMS OSRAM INT GMBH [DE]
ams-OSRAM International GmbH

Resumen de: US2025040841A1

A method for determining a substance concentration in a particle-containing liquid, in particular of glucose in blood, wherein a refractive index of the liquid is dependent on a concentration of the substance dissolved therein, includes emitting a measuring light beam of at least one wavelength onto a sample containing the liquid. The method also includes detecting a first light component scattered by scattering on the particles contained in the liquid at a first angle, which corresponds in particular to a forward scattering of the light component. The method further includes detecting a second light component scattered at a second angle by the particles contained in the liquid. The method additionally includes determining a concentration or a proportion of the substance in the liquid from the detected first and second light components, in particular by forming a ratio from the detected first and second light components.